Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, April 02, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 141,000 restricted stock units to eleven new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee’s acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The 141,000 restricted s